logo

Oncosec Medical Inc (ONCS)



Trade ONCS now with
  Date
  Headline
8/27/2020 8:35:05 AM OncoSec Begins Phase 2 Study To Evaluate The Combination Of TAVO Plus OPDIVO® As Neoadjuvant Therapy For Melanoma
8/17/2020 12:07:07 AM OncoSec Medical Enters Purchase Agreements For Purchase Of 4.61 Mln Shares At $3.25/Shr
7/27/2020 9:12:30 AM OncoSec Names Kellie Malloy Foerter COO
7/13/2020 9:07:50 AM OncoSec Announces Promising Potential Of Novel DNA–encodable Vaccine Candidate, CORVax12 To Prevent COVID-19
6/22/2020 9:06:01 AM OncoSec Presents Two Late-Breaking Abstracts On TAVO-PLUS
6/9/2020 9:09:20 AM OncoSec Medical Expands KEYNOTE-890 Trial Into First-Line MTNBC With TAVO And KEYTRUDA Plus Chemotherapy
5/13/2020 9:24:11 AM OncoSec's TAVO Gets ATMP Certification From EMA To Support Marketing Authorization Application In Metastatic Melanoma
5/6/2020 9:08:51 AM OncoSec: TAVO -KEYTRUDA Shows 41% Overall Response Rate & 36% Complete Response In Late-Stage Metastatic Melanoma Study
4/21/2020 9:07:15 AM OncoSec : VLA And APOLLO Feasibility Study Shows TAVO Can Be Safely Delivered And Electroporated In Liver
4/6/2020 9:27:23 AM OncoSec Collaborates With Providence Cancer Institute To Conduct First-in-Human Trial Of OncoSec's CORVax12
3/17/2020 8:33:41 AM OncoSec Announces Publication Of Positive TAVO Monotherapy Results In Metastatic Melanoma Patients In Annals Of Oncology
3/11/2020 8:35:03 AM OncoSec Receives $850K From The Australian R&D Tax Incentive Program For TAVO R&D Work In 2019
3/9/2020 8:33:10 AM OncoSec Says Class Action And Related Litigation Brought By Alpha Dismissed By Nevada State Court With Prejudice
2/11/2020 8:32:50 AM OncoSec Medical Adds Yuhang Zhao, Chao Zhou And Kevin Smith As New Members Of Board
2/7/2020 8:06:39 AM OncoSec Says Nevada Court Denies Alpha Holdings' Motion To Enjoin Special Meeting Of Shareholders
2/3/2020 9:56:19 AM Alpha Urges OncoSec Stockholders To Vote Against China Grand Takeover On BLUE Proxy Card Only